{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:58:03Z","timestamp":1789466283326,"version":"build-2803163510"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s11892-022-01452-5","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T05:02:30Z","timestamp":1644987750000},"page":"53-63","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["COVID-19 and Diabetes Outcomes: Rationale for and Updates from the CORONADO Study"],"prefix":"10.1007","volume":"22","author":[{"given":"Sarra","family":"Smati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blandine","family":"Tramunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Wargny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Gourdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Hadjadj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Cariou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,16]]},"reference":[{"key":"1452_CR1","first-page":"1054","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet Lancet Publishing Group. 2020;395:1054\u201362.","journal-title":"Lancet Lancet Publishing Group"},{"key":"1452_CR2","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/j.1464-5491.2006.01861.x","volume":"23","author":"JK Yang","year":"2006","unstructured":"Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med Diabet Med. 2006;23:623\u20138.","journal-title":"Diabet Med Diabet Med"},{"key":"1452_CR3","doi-asserted-by":"crossref","unstructured":"Alqahtani FY, Aleanizy FS, Ali El Hadi Mohamed R, Alanazi MS, Mohamed N, Alrasheed MM, et al. Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: A retrospective study. Epidemiol Infect. Cambridge University Press; 2019;147.","DOI":"10.1017\/S0950268818002923"},{"key":"1452_CR4","doi-asserted-by":"crossref","unstructured":"Singh AK, Gillies CL, Singh R, Singh A, Chudasama Y, Coles B, et al. Prevalence of co-morbidities and their association with mortality in patients with COVID-19: A systematic review and meta-analysis. Diabetes, Obes Metab. 2020;","DOI":"10.1111\/dom.14124"},{"key":"1452_CR5","doi-asserted-by":"crossref","unstructured":"Vas PRJ, Hopkins D, Feher MD, Rubino F, Martin MB. Diabetes, obesity and COVID-19: a complex interplay. Diabetes, Obes Metab. 2020;","DOI":"10.1111\/dom.14134"},{"key":"1452_CR6","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","volume":"584","author":"EJ Williamson","year":"2020","unstructured":"\u2022\u2022 Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature Nature Research. 2020;584:430\u20136. (Using the English platform OpenSAFELY, Williamson et al. examined factors associated with COVID-19-related death.)","journal-title":"Nature Nature Research"},{"key":"1452_CR7","doi-asserted-by":"crossref","unstructured":"Semenzato L, Botton J, Drouin J, Cuenot F, Dray-Spira R, Weill A, et al. Chronic diseases, health conditions and risk of COVID-19-related hospitalization and in-hospital mortality during the first wave of the epidemic in France: a cohort study of 66 million people. Lancet Reg Heal - Eur. Elsevier BV; 2021;8:100158.","DOI":"10.1016\/j.lanepe.2021.100158"},{"key":"1452_CR8","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1007\/s00125-020-05180-x","volume":"63","author":"B Cariou","year":"2020","unstructured":"\u2022 Cariou B, Hadjadj S, Wargny M, Pichelin M, Al-Salameh A, Allix I, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia Springer. 2020;63:1500\u201315. (The first interim analysis of the CORONADO study reporting the characteristics related to poor early prognosis factors (IMV and\/or death within D7).)","journal-title":"Diabetologia Springer"},{"key":"1452_CR9","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.diabet.2011.02.001","volume":"37","author":"C Pornet","year":"2011","unstructured":"Pornet C, Bourdel-Marchasson I, Lecomte P, Eschw\u00e8ge E, Romon I, Fosse S, et al. Trends in the quality of care for elderly people with type 2 diabetes: the need for improvements in safety and quality (The 2001 and 2007 ENTRED Surveys). Diabetes Metab Diabetes Metab. 2011;37:152\u201361.","journal-title":"Diabetes Metab Diabetes Metab"},{"key":"1452_CR10","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Wargny M, Potier L, Gourdy P, Pichelin M, Amadou C, Benhamou PY, et al. Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study. Diabetologia [Internet]. Diabetologia; 2021 [cited 2021 Mar 31];64:778\u201394. Available from: http:\/\/link.springer.com\/10.1007\/s00125-020-05351-w. (Identification of prognosis factors for IMV, death or discharge within D28.)","DOI":"10.1007\/s00125-020-05351-w"},{"key":"1452_CR11","doi-asserted-by":"crossref","unstructured":"Satman I, Demirci I, Haymana C, Tasci I, Salman S, Ata N, et al. Unexpectedly lower mortality rates in COVID-19 patients with and without type 2 diabetes in Istanbul. Diabetes Res Clin Pract [Internet]. Elsevier; 2021 [cited 2021 Mar 22];108753. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822721001066","DOI":"10.1016\/j.diabres.2021.108753"},{"key":"1452_CR12","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S2213-8587(20)30405-8","volume":"9","author":"SJ McGurnaghan","year":"2021","unstructured":"McGurnaghan SJ, Weir A, Bishop J, Kennedy S, Blackbourn LAK, McAllister DA, et al. Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. Lancet Diabetes Endocrinol Lancet Publishing Group. 2021;9:82\u201393.","journal-title":"Lancet Diabetes Endocrinol Lancet Publishing Group"},{"key":"1452_CR13","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.mayocp.2020.05.014","volume":"95","author":"M Alkhouli","year":"2020","unstructured":"Alkhouli M, Nanjundappa A, Annie F, Bates MC, Bhatt DL. Sex Differences in Case Fatality Rate of COVID-19: Insights From a Multinational Registry. Mayo Clin Proc Elsevier Ltd. 2020;95:1613\u201320.","journal-title":"Mayo Clin Proc Elsevier Ltd"},{"key":"1452_CR14","doi-asserted-by":"crossref","unstructured":"Peckham H, De Gruijter N, Raine C, Radziszewska A, Ciurtin C, Wedderburn L, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun [Internet]. Nature Publishing Group; 2020 [cited 2020 Dec 10];11:6317. Available from: http:\/\/www.nature.com\/articles\/s41467-020-19741-6","DOI":"10.1038\/s41467-020-19741-6"},{"key":"1452_CR15","doi-asserted-by":"crossref","unstructured":"Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. Biol. Sex Differ. BioMed Central Ltd.; 2020.","DOI":"10.1186\/s13293-020-00304-9"},{"key":"1452_CR16","doi-asserted-by":"crossref","unstructured":"Penna C, Mercurio V, Tocchetti CG, Pagliaro P. Sex\u2010related differences in COVID\u201019 lethality. Br J Pharmacol [Internet]. John Wiley and Sons Inc.; 2020 [cited 2020 Dec 12];177:bph.15207. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/bph.15207","DOI":"10.22541\/au.159050901.11107519"},{"key":"1452_CR17","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41577-020-0348-8","volume":"20","author":"EP Scully","year":"2020","unstructured":"Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. Considering how biological sex impacts immune responses and COVID-19 outcomes. Nat Rev Immunol Nature Research. 2020;20:442\u20137.","journal-title":"Nat Rev Immunol Nature Research"},{"key":"1452_CR18","doi-asserted-by":"crossref","unstructured":"Bunders MJ, Altfeld M. Implications of Sex Differences in Immunity for SARS-CoV-2 Pathogenesis and Design of Therapeutic Interventions. Immunity. Cell Press; 2020. p. 487\u201395.","DOI":"10.1016\/j.immuni.2020.08.003"},{"key":"1452_CR19","doi-asserted-by":"crossref","unstructured":"de Jong M, Woodward M, Peters SAE. Diabetes and COVID-19-related mortality in women and men in the UK Biobank: comparisons with influenza\/pneumonia and coronary heart disease. Diabetes Care [Internet]. Diabetes Care; 2020 [cited 2020 Dec 14]; Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33293345","DOI":"10.2337\/dc20-2378"},{"key":"1452_CR20","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1530\/EJE-21-0068","volume":"185","author":"B Tramunt","year":"2021","unstructured":"Tramunt B, Smati S, Coudol S, Wargny M, Pichelin M, Guyomarch B, et al. Sex disparities in COVID-19 outcomes of inpatients with diabetes: Insights from the CORONADO study. Eur J Endocrinol BioScientifica Ltd. 2021;185:299\u2013311.","journal-title":"Eur J Endocrinol BioScientifica Ltd"},{"key":"1452_CR21","doi-asserted-by":"crossref","unstructured":"Caussy C, Pattou F, Wallet F, Simon C, Chalopin S, Telliam C, et al. Prevalence of obesity among adult inpatients with COVID-19 in France. Lancet Diabetes Endocrinol [Internet]. Elsevier; 2020 [cited 2020 May 25];0. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213858720301601","DOI":"10.1016\/S2213-8587(20)30160-1"},{"key":"1452_CR22","doi-asserted-by":"crossref","unstructured":"Gunst J, De Bruyn A, Van Den Berghe G. Glucose control in the ICU. Curr Opin Anaesthesiol [Internet]. Lippincott Williams and Wilkins; 2019 [cited 2020 Apr 12];32:156\u201362. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30817388","DOI":"10.1097\/ACO.0000000000000706"},{"key":"1452_CR23","doi-asserted-by":"crossref","unstructured":"Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity. 2020;0\u20131.","DOI":"10.1002\/oby.22831"},{"key":"1452_CR24","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/S2213-8587(20)30271-0","volume":"8","author":"N Holman","year":"2020","unstructured":"\u2022\u2022 Holman N, Knighton P, Kar P, O\u2019Keefe J, Curley M, Weaver A, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol Lancet Publishing Group. 2020;8:823\u201333. (In England, authors assessed associations between risk factors and COVID-19-related mortality in people with type 1 and type 2 diabetes.)","journal-title":"Lancet Diabetes Endocrinol Lancet Publishing Group"},{"key":"1452_CR25","doi-asserted-by":"crossref","unstructured":"Smati S, Tramunt B, Wargny M, Caussy C, Gaborit B, Vatier C, et al. Relationship between obesity and severe COVID-19 outcomes in patients with type 2 diabetes: results from the CORONADO study. Diabetes, Obes Metab. Wiley; 2021;23:391\u2013403.","DOI":"10.1111\/dom.14228"},{"key":"1452_CR26","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S2213-8587(21)00089-9","volume":"9","author":"M Gao","year":"2021","unstructured":"Gao M, Piernas C, Astbury NM, Hippisley-Cox J, O\u2019Rahilly S, Aveyard P, et al. Associations between body-mass index and COVID-19 severity in 6\u00b79 million people in England: a prospective, community-based, cohort study. Lancet Diabetes Endocrinol Lancet Publishing Group. 2021;9:350\u20139.","journal-title":"Lancet Diabetes Endocrinol Lancet Publishing Group"},{"key":"1452_CR27","doi-asserted-by":"crossref","unstructured":"Blanchard C, Perennec T, Smati S, Tramunt B, Guyomarch B, Bigot-Corbel E, et al. History of bariatric surgery and COVID 19 outcomes in patients with type 2 diabetes: results from the CORONADO study. Obesity (Silver Spring) [Internet]. 2021 [cited 2021 Oct 17]; Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34586754","DOI":"10.1002\/oby.23314"},{"key":"1452_CR28","doi-asserted-by":"crossref","unstructured":"Wargny M, Gourdy P, Ludwig L, Seret-B\u00e9gu\u00e9 D, Bourron O, Darmon P, et al. Type 1 diabetes in people hospitalized for covid-19: New insights from the coronado study. Diabetes Care. American Diabetes Association Inc.; 2020. p. e174\u20137.","DOI":"10.2337\/figshare.12728246"},{"key":"1452_CR29","doi-asserted-by":"crossref","unstructured":"Vangoitsenhoven R, Martens PJ, van Nes F, Moyson C, Nobels F, Van Crombrugge P, et al. No evidence of increased hospitalization rate for covid-19 in community-dwelling patients with type 1 diabetes. Diabetes Care. American Diabetes Association Inc.; 2020;43:e118\u20139.","DOI":"10.2337\/dc20-1246"},{"key":"1452_CR30","doi-asserted-by":"crossref","unstructured":"Ruan Y, Ryder REJ, De P, Field BCT, Narendran P, Iqbal A, et al. A UK nationwide study of people with type 1 diabetes admitted to hospital with COVID-19 infection. Diabetologia. Springer Science and Business Media Deutschland GmbH; 2021;64:1717\u201324.","DOI":"10.1007\/s00125-021-05463-x"},{"key":"1452_CR31","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S2213-8587(20)30272-2","volume":"8","author":"E Barron","year":"2020","unstructured":"\u2022\u2022 Barron E, Bakhai C, Kar P, Weaver A, Bradley D, Ismail H, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol Lancet Publishing Group. 2020;8:813\u201322. (This nationwide analysis in England showed that type 1 and type 2 diabetes were both independently associated with in-hospital death with COVID-19.)","journal-title":"Lancet Diabetes Endocrinol Lancet Publishing Group"},{"key":"1452_CR32","doi-asserted-by":"crossref","unstructured":"Nassar M, Nso N, Baraka B, Alfishawy M, Mohamed M, Nyabera A, et al. The association between COVID-19 and type 1 diabetes mellitus: a systematic review. Diabetes Metab. Syndr. Clin. Res. Rev. Elsevier Ltd; 2021. p. 447\u201354.","DOI":"10.1016\/j.dsx.2021.02.009"},{"key":"1452_CR33","doi-asserted-by":"crossref","unstructured":"O\u2019Malley G, Ebekozien O, Desimone M, Pinnaro CT, Roberts A, Polsky S, et al. COVID-19 hospitalization in adults with type 1 diabetes: results from the T1D exchange multicenter surveillance study. J Clin Endocrinol Metab [Internet]. Endocrine Society; 2021 [cited 2021 Nov 2];106:e936\u201342. Available from: https:\/\/academic.oup.com\/jcem\/article\/106\/2\/e936\/5963916","DOI":"10.1210\/clinem\/dgaa825"},{"key":"1452_CR34","doi-asserted-by":"crossref","unstructured":"Singh AK, Khunti K. COVID-19 and diabetes. Annu Rev Med. 2021;73.","DOI":"10.1146\/annurev-med-042220-011857"},{"key":"1452_CR35","doi-asserted-by":"crossref","unstructured":"Rubino F, Amiel SA, Zimmet P, Alberti G, Bornstein S, Eckel RH, et al. New-Onset Diabetes in Covid-19. N Engl J Med. Massachusetts Medical Society; 2020;383:789\u201390.","DOI":"10.1056\/NEJMc2018688"},{"key":"1452_CR36","doi-asserted-by":"crossref","unstructured":"Khunti K, Del Prato S, Mathieu C, Kahn SE, Gabbay RA, Buse JB. COVID-19, hyperglycemia, and new-onset diabetes. Diabetes Care. American Diabetes Association; 2021;dc211318.","DOI":"10.2337\/dc21-1318"},{"key":"1452_CR37","doi-asserted-by":"crossref","unstructured":"Cariou B, Pichelin M, Goronflot T, Gonfroy C, Marre M, Raffaitin-Cardin C, et al. Phenotypic characteristics and prognosis of newly diagnosed diabetes in hospitalized patients with COVID-19: Results from the CORONADO study. Diabetes Res Clin Pract. Elsevier Ireland Ltd; 2021;175.","DOI":"10.1016\/j.diabres.2021.108695"},{"key":"1452_CR38","doi-asserted-by":"crossref","unstructured":"Sathish T, Kapoor N, Cao Y, Tapp RJ, Zimmet P. Proportion of newly diagnosed diabetes in COVID-19 patients: a systematic review and meta-analysis. Diabetes, Obes. Metab. Blackwell Publishing Ltd; 2021. p. 870\u20134.","DOI":"10.1111\/dom.14269"},{"key":"1452_CR39","doi-asserted-by":"crossref","unstructured":"Agarwal S, Mathew J, Davis GM, Shephardson A, Levine A, Louard R, et al. Continuous glucose monitoring in the intensive care unit during the COVID-19 pandemic. Diabetes Care. American Diabetes Association Inc.; 2021;44:847\u20139.","DOI":"10.2337\/dc20-2219"},{"key":"1452_CR40","doi-asserted-by":"publisher","unstructured":"Zhu L, She Z-G, Cheng X, Qin J-J, Zhang X-J, Cai J, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab [Internet]. Elsevier; 2020 [cited 2020 May 5]; Available from:\u00a0https:\/\/doi.org\/10.1016\/j.cmet.2020.04.021","DOI":"10.1016\/j.cmet.2020.04.021"},{"key":"1452_CR41","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1007\/s00125-020-05209-1","volume":"63","author":"S Wang","year":"2020","unstructured":"Wang S, Ma P, Zhang S, Song S, Wang Z, Ma Y, et al. Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study. Diabetologia Springer. 2020;63:2102\u201311.","journal-title":"Diabetologia Springer"},{"key":"1452_CR42","doi-asserted-by":"crossref","unstructured":"Wu J, Huang J, Zhu G, Wang Q, Lv Q, Huang Y, et al. Elevation of blood glucose level predicts worse outcomes in hospitalized patients with COVID-19: a retrospective cohort study. BMJ Open Diabetes Res Care. BMJ Publishing Group; 2020;8.","DOI":"10.1136\/bmjdrc-2020-001476"},{"key":"1452_CR43","doi-asserted-by":"crossref","unstructured":"Cai Y, Shi S, Yang F, Yi B, Chen X, Li J, et al. Fasting blood glucose level is a predictor of mortality in patients with COVID-19 independent of diabetes history. Diabetes Res Clin Pract. Elsevier Ireland Ltd; 2020;169.","DOI":"10.1016\/j.diabres.2020.108437"},{"key":"1452_CR44","doi-asserted-by":"crossref","unstructured":"Davis GM, Faulds E, Walker T, Vigliotti D, Rabinovich M, Hester J, et al. Remote continuous glucose monitoring with a computerized insulin infusion protocol for critically ill patients in a COVID-19 medical ICU: proof of concept. Diabetes Care. American Diabetes Association Inc.; 2021;44:1055\u20138.","DOI":"10.2337\/dc20-2085"},{"key":"1452_CR45","doi-asserted-by":"crossref","unstructured":"Longo RR, Elias H, Khan M, Seley JJ. Use and accuracy of inpatient CGM during the COVID-19 pandemic: an observational study of general medicine and ICU patients. J Diabetes Sci Technol. SAGE Publications Inc.; 2021;","DOI":"10.1177\/19322968211008446"},{"key":"1452_CR46","doi-asserted-by":"crossref","unstructured":"Klarskov CK, Windum NA, Olsen MT, Dungu AM, Jensen AK, Lindegaard B, et al. Telemetric continuous glucose monitoring during the COVID-19 pandemic in isolated hospitalized patients in Denmark
 \u2013 a randomized controlled exploratory trial. Diabetes Technol Ther [Internet]. Diabetes Technol Ther; 2021 [cited 2021 Sep 30]; Available from: https:\/\/www.liebertpub.com\/doi\/10.1089\/dia.2021.0291","DOI":"10.1089\/dia.2021.0291"},{"key":"1452_CR47","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/S2213-8587(21)00180-7","volume":"9","author":"MN Kosiborod","year":"2021","unstructured":"Kosiborod MN, Esterline R, Furtado RHM, Oscarsson J, Gasparyan SB, Koch GG, et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol Lancet Publishing Group. 2021;9:586\u201394.","journal-title":"Lancet Diabetes Endocrinol Lancet Publishing Group"},{"key":"1452_CR48","doi-asserted-by":"crossref","unstructured":"Lalau J-D, Al-Salameh A, Hadjadj S, Goronflot T, Wiernsperger N, Pichelin M, et al. Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19. Diabetes Metab. Elsevier BV; 2020;101216.","DOI":"10.1016\/j.diabet.2020.101216"},{"key":"1452_CR49","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S2213-8587(21)00050-4","volume":"9","author":"K Khunti","year":"2021","unstructured":"Khunti K, Knighton P, Zaccardi F, Bakhai C, Barron E, Holman N, et al. Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England. Lancet Diabetes Endocrinol Lancet Publishing Group. 2021;9:293\u2013303.","journal-title":"Lancet Diabetes Endocrinol Lancet Publishing Group"},{"key":"1452_CR50","doi-asserted-by":"crossref","unstructured":"Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat. Rev. Endocrinol. Nature Research; 2021. p. 11\u201330.","DOI":"10.1038\/s41574-020-00435-4"},{"key":"1452_CR51","doi-asserted-by":"crossref","unstructured":"Al-Salameh A, Bennis Y, Cariou B, Lalau J-D. The association between metformin treatment and COVID-19 outcomes according to metformin continuation during hospitalisation. Diabetes Metab [Internet]. Diabetes Metab; 2021 [cited 2021 Nov 2];101297. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S126236362100080X","DOI":"10.1016\/j.diabet.2021.101297"},{"key":"1452_CR52","doi-asserted-by":"crossref","unstructured":"Bramante CT, Ingraham NE, Murray TA, Marmor S, Hovertsen S, Gronski J, et al. Observational study of metformin and risk of mortality in patients hospitalized with Covid-19. medRxiv. medRxiv; 2020.","DOI":"10.1101\/2020.06.19.20135095"},{"key":"1452_CR53","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nature12005","volume":"495","author":"VS Raj","year":"2013","unstructured":"Raj VS, Mou H, Smits SL, Dekkers DHW, M\u00fcller MA, Dijkman R, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature Nature. 2013;495:251\u20134.","journal-title":"Nature Nature"},{"key":"1452_CR54","doi-asserted-by":"crossref","unstructured":"Drucker DJ. Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning. Cell Metab. Cell Press; 2021. p. 479\u201398.","DOI":"10.1016\/j.cmet.2021.01.016"},{"key":"1452_CR55","doi-asserted-by":"crossref","unstructured":"Nauck MA, Meier JJ. Reduced covid-19 mortality with sitagliptin treatment? Weighing the dissemination of potentially lifesaving findings against the assurance of high scientific standards. Diabetes Care. American Diabetes Association Inc.; 2020. p. 2906\u20139.","DOI":"10.2337\/dci20-0062"},{"key":"1452_CR56","unstructured":"Roussel R, Darmon P, Pichelin M, Goronflot T, Abouleka Y, Ait Bachir L, et al. Use of Dipeptidyl Peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: a propensity score analysis from the CORONADO study. Diabetes Obes Metab [Internet]. Diabetes Obes Metab; 2021 [cited 2021 Feb 4]; Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33528920"},{"key":"1452_CR57","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Belmonte LM, Torres-Pe\u00f1a JD, L\u00f3pez-Carmona MD, Ayala-Guti\u00e9rrez MM, Fuentes-Jim\u00e9nez F, Huerta LJ, et al. Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study. BMC Med [Internet]. BioMed Central Ltd; 2020 [cited 2021 Nov 2];18:359. Available from: https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-020-01832-2","DOI":"10.1186\/s12916-020-01832-2"},{"key":"1452_CR58","doi-asserted-by":"crossref","unstructured":"Yang Y, Cai Z, Zhang J. Insulin treatment may increase adverse outcomes in patients with COVID-19 and diabetes: a systematic review and meta-analysis. Front Endocrinol (Lausanne). Frontiers Media S.A.; 2021;12.","DOI":"10.3389\/fendo.2021.696087"},{"key":"1452_CR59","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.cmet.2020.11.015","volume":"33","author":"MY Donath","year":"2021","unstructured":"Donath MY. Glucose or Insulin, Which is the culprit in patients with COVID-19 and diabetes? Cell Metab Cell Press. 2021;33:2\u20134.","journal-title":"Cell Metab Cell Press"},{"key":"1452_CR60","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cmet.2020.06.015","volume":"32","author":"XJ Zhang","year":"2020","unstructured":"Zhang XJ, Qin JJ, Cheng X, Shen L, Zhao YC, Yuan Y, et al. In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metab Cell Press. 2020;32:176-187.e4.","journal-title":"Cell Metab Cell Press"},{"key":"1452_CR61","doi-asserted-by":"crossref","unstructured":"Scheen AJ. Statins and clinical outcomes with COVID-19: meta-analyses of observational studies. Diabetes Metab. Elsevier BV; 2020;101220.","DOI":"10.1016\/j.diabet.2020.101220"},{"key":"1452_CR62","doi-asserted-by":"crossref","unstructured":"Cariou B, Goronflot T, Rimbert A, Boullu S, Le May C, Moulin P, et al. Routine use of statins and increased COVID-19 related mortality in inpatients with type 2 diabetes: results from the CORONADO study. Diabetes Metab. 2020;","DOI":"10.1016\/j.diabet.2020.10.001"},{"key":"1452_CR63","doi-asserted-by":"crossref","unstructured":"Yetmar ZA, Challener DW, Tleyjeh IM, Sohail MR, Cerhan JR, Badley AD, et al. Association between chronic statin use and 30-day mortality in hospitalized patients with COVID-19. Mayo Clin Proc Innov Qual Outcomes. Elsevier BV; 2021;5:442\u20136.","DOI":"10.1016\/j.mayocpiqo.2021.02.002"},{"key":"1452_CR64","first-page":"114","volume":"330","author":"A Kollias","year":"2021","unstructured":"Kollias A, Kyriakoulis KG, Kyriakoulis IG, Nitsotolis T, Poulakou G, Stergiou GS, et al. Statin use and mortality in COVID-19 patients: updated systematic review and meta-analysis. Atherosclerosis Elsevier Ireland Ltd. 2021;330:114\u201321.","journal-title":"Atherosclerosis Elsevier Ireland Ltd"},{"key":"1452_CR65","doi-asserted-by":"crossref","unstructured":"McAlister FA, Wang T, Wang X, Chu A, Goodman SG, van Diepen S, et al. Statins and SARS\u2010CoV\u20102 infection: results of a population\u2010based prospective cohort study of 469\u00a0749 adults from 2 Canadian provinces. J Am Heart Assoc. Ovid Technologies (Wolters Kluwer Health); 2021;10.","DOI":"10.1161\/JAHA.121.022330"},{"key":"1452_CR66","doi-asserted-by":"crossref","unstructured":"Corona G, Pizzocaro A, Vena W, Rastrelli G, Semeraro F, Isidori AM, et al. Diabetes is most important cause for mortality in COVID-19 hospitalized patients: systematic review and meta-analysis. Rev. Endocr. Metab. Disord. Springer; 2021. p. 275\u201396.","DOI":"10.1007\/s11154-021-09630-8"},{"key":"1452_CR67","doi-asserted-by":"crossref","unstructured":"Sutter W, Duceau B, Vignac M, Bonnet G, Carlier A, Roussel R, et al. Association of diabetes and outcomes in patients with COVID-19: propensity score-matched analyses from a French retrospective cohort. Diabetes Metab. Elsevier Masson s.r.l.; 2021;47.","DOI":"10.1016\/j.diabet.2020.101222"},{"key":"1452_CR68","doi-asserted-by":"publisher","first-page":"E3364","DOI":"10.1210\/clinem\/dgab393","volume":"106","author":"M Diedisheim","year":"2021","unstructured":"Diedisheim M, Dancoisne E, Gautier JF, Larger E, Cosson E, F\u00e8ve B, et al. Diabetes increases severe COVID-19 outcomes primarily in younger adults. J Clin Endocrinol Metab Endocrine Society. 2021;106:E3364\u20138.","journal-title":"J Clin Endocrinol Metab Endocrine Society"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-022-01452-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11892-022-01452-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-022-01452-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T15:14:32Z","timestamp":1700234072000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11892-022-01452-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":68,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1452"],"URL":"https:\/\/doi.org\/10.1007\/s11892-022-01452-5","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"16 February 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SH reports grants, non-financial support or personal fees from Air Liquid, Allergan, Astra Zeneca, Bayer, Boehringer Ingelheim, Dinno Sant\u00e9, Eli Lilly, Elivie, Fortil, Lifescan, LVL, Merck Sharpe Dome, NHC, Novartis, Pierre Fabre Sant\u00e9, Sanofi, Servier, and Valbiotis. PG reports grants or personal fees from Abbott, Air Liquid, Allergan, Amgen, Astra-Zeneca, Boehringer Ingelheim, Eli Lilly, Elivie, Fortil, Lifescan, Merck Sharp and Dohme, Mundipharma, NHC, Novo Nordisk, Sanofi, and Servier. BC reports grants, non-financial support or personal fees from Abbott, Allergan, Amgen, Akcea AstraZeneca, Pierre Fabre, Genfit, Gilead, Eli Lilly, Elivie, Fortil, Lifescan, Merck Sharpe Dome, NHC, Novo Nordisk, Regeneron and Sanofi. MW reports personal fees from Novo Nordisk. Other authors report no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}